Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT00492895
First received: June 19, 2007
Last updated: January 28, 2013
Last verified: January 2013
  Purpose

Photosensitivity of the skin to UVA and UVB will be determined


Condition Intervention Phase
Skin Cancer
Drug: Discontinuation of Azathioprin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Photosensitivity of the skin to UVA and UVB [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: June 2007
Study Completion Date: March 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A
one arm only. Crossover study
Drug: Discontinuation of Azathioprin
Discontinuation of Azathioprin
Other Name: Discontinuation of Azathioprin

Detailed Description:

Photosensitivity of the skin to UVA and UVB in renal transplant recipients with and without azathioprine will be determined. Azathioprine will be discontinued and photosensitivity determined after a wash-out period of three months

  • Trial with medicinal product
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Renal transplant recipients under azathioprin

Exclusion criteria:

  • Treatment with Prograf (Tacrolimus)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00492895

Locations
Switzerland
Clinic for Dermatology, University Hospital of Zurich
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Günther Hofbauer, M.D UniversitaetsSpital Zuerich
  More Information

Publications:
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT00492895     History of Changes
Other Study ID Numbers: 2007DR2040
Study First Received: June 19, 2007
Last Updated: January 28, 2013
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Neoplasms
Skin Diseases

ClinicalTrials.gov processed this record on April 17, 2014